Literature DB >> 6140850

Immunohistochemical study of pheochromocytomas. An investigation of methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin in 16 tumors.

J Hassoun, G Monges, P Giraud, J F Henry, C Charpin, H Payan, M Toga.   

Abstract

Immunohistochemical investigations were carried out on 16 pheochromocytomas for a study of their immunoreactivity to methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin on serial semithin araldite sections. All antiserums except anti-beta-endorphin, selectively stained a variable number of distinct tumor cells. Methionine-enkephalin-immunoreactive cells were the most frequent. The neuropeptide content of pheochromocytomas appears highly diverse and unpredictable. These findings are supportive of the concept of multisecretory APUD cells of neural crest origin and rule out any of these neuropeptides as reliable immunohistochemical markers for tumor chromaffin cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6140850      PMCID: PMC1900405     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  ACTH secretion from a functioning pheochromocytoma.

Authors:  R F Spark; P B Connolly; D S Gluckin; R White; B Sacks; L Landsberg
Journal:  N Engl J Med       Date:  1979-08-23       Impact factor: 91.245

2.  Watery diarrhea syndrome. Two unusual cases and further evidence that VIP is a humoral mediator.

Authors:  A M Cooperman; D Desantis; E Winkelman; R Farmer; J Eversman; S Said
Journal:  Ann Surg       Date:  1978-03       Impact factor: 12.969

3.  Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla.

Authors:  M Schultzberg; J M Lundberg; T Hökfelt; L Terenius; J Brandt; R P Elde; M Goldstein
Journal:  Neuroscience       Date:  1978       Impact factor: 3.590

4.  Content of beta-LPH and its fragments (including endorphins) in anterior and intermediate lobes of the bovine pituitary gland.

Authors:  J C Lissitsky; O Morin; A Dupont; F Labrie; N G Seidah; M Chrétien; M Lis; D H Coy
Journal:  Life Sci       Date:  1978-05-15       Impact factor: 5.037

5.  Enkephalin in peripheral neuroendocrine tumours.

Authors:  S N Sullivan; S R Bloom; J M Polak
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

6.  Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors.

Authors:  G Mendelsohn; J C Eggleston; J L Olson; S I Said; S B Baylin
Journal:  Lab Invest       Date:  1979-08       Impact factor: 5.662

7.  Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

Authors:  G J Krejs; L Orci; J M Conlon; M Ravazzola; G R Davis; P Raskin; S M Collins; D M McCarthy; D Baetens; A Rubenstein; T A Aldor; R H Unger
Journal:  N Engl J Med       Date:  1979-08-09       Impact factor: 91.245

8.  Hypercalcitoninaemia in patients with pheochromocytoma.

Authors:  F Raue; J M Bayer; K H Rahn; C Herfarth; H Minne; R Ziegler
Journal:  Klin Wochenschr       Date:  1978-07-15

9.  Immunoreactive somatostatin in rat hypophysial portal blood.

Authors:  P Gillioz; P Giraud; B Conte-Devolx; P Jaquet; J L Codaccioni; C Oliver
Journal:  Endocrinology       Date:  1979-05       Impact factor: 4.736

10.  Ectopic ACTH syndrome due to pheochromocytoma: case report and review of the literature.

Authors:  B H Forman; E Marban; R D Kayne; N M Passarelli; S N Bobrow; V A Livolsi; M Merino; M Minor; L R Farber
Journal:  Yale J Biol Med       Date:  1979 Mar-Apr
View more
  13 in total

1.  Augmented enkephalin-immunoreactivity in adrenaline-producing phaeochromocytomas.

Authors:  T Kodama; C Ito; Y Fujimoto; Y Ito; T Obara; A Hirayama
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Prostate-specific acid phosphatase in carcinoid tumors.

Authors:  N Kimura; N Sasano
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

3.  Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level.

Authors:  G K Haselbacher; J C Irminger; J Zapf; W H Ziegler; R E Humbel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

4.  In vivo desensitization of glycogenolysis to Ca2+-mobilizing hormones in rat liver cells.

Authors:  G Tsujimoto; A Tsujimoto; K Kato; K Hashimoto
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Assessment of adrenal surgery on creatinine clearance in patients with phaeochromocytoma.

Authors:  T Nakada; H Kaneko; Y Kubota; M Watanabe; I Sasagawa; T Yagisawa; H Yamanaka; K Imai
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

6.  High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991.

Authors:  C Proye; M Vix; A Goropoulos; P Kerlo; M Lecomte-Houcke
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

7.  Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour.

Authors:  N Kimura; N Sasano; R Yamada; J Satoh
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  A retroperitoneal sympathetic paraganglioma invading the duodenum and mimicking a submucosal tumor.

Authors:  Noriko Kimura; Takuzo Ishidate; Takahiro Kogawa; Yukio Miura; Masanori Ishizaka; Masami Ogita
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 9.  Endocrine cells producing regulatory peptides.

Authors:  E Solcia; L Usellini; R Buffa; G Rindi; L Villani; C Zampatti; E Silini
Journal:  Experientia       Date:  1987-07-15

10.  Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas.

Authors:  E Baldi; M L De Feo; P Geppetti; V Carlà; M Maggi; C Pupilli; M G Spillantini; A Brocchi; M Mannelli
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.